NortheastPop. 3.6M

GLP-1 Coverage & Costs in Connecticut (2026)

$79/month (Embody, compounded semaglutide, monthly plan) is the lowest monthly-plan price we have recorded among the programs on this page. Embody lists 48 states and our records do not name them, so confirm Connecticut at intake.

The lowest recorded compounded tirzepatide price is $129/month (Embody, monthly plan). Among programs recorded as available in all 50 states, the lowest is $139/month (AgelessRx, compounded semaglutide, monthly plan). 6 of the 49 programs listed have no recorded price. Recorded prices cover medication and known program fees, not a verified total.

Medicaid: not covered as of January 2026 (KFF)
Eduard Cristea
Eduard Cristea
Published: |Updated:

Connecticut Medicaid Coverage for GLP-1

Medicaid: not covered as of January 2026 (KFF)

KFF's map lists Connecticut as not covering GLP-1s for obesity under fee-for-service as of January 2026. KFF notes the state reported covering one or more weight-loss drugs, but no GLP-1s. Rules and later changes are not on that map, so confirm with the state Medicaid agency or your plan.

Your Options in Connecticut:

  • Telehealth programs: recorded compounded prices from $79/month on a monthly plan, where the program serves Connecticut
  • Commercial or employer insurance: check your plan's drug list and prior authorization rules
  • Medicare GLP-1 Bridge for eligible Part D enrollees (see below)

Connecticut Medicaid GLP-1 Prescriptions in 2025

Prescriptions paid

174,430

Rank of 51

#16

Medicaid paid, before rebates

$199.9 million

Most-filled product

Ozempic

Connecticut Medicaid paid for 174,430 GLP-1 prescriptions in 2025, 1.5% of the 11.26 million paid nationally and number 16 of 51 (50 states and DC). It reimbursed pharmacies $199.9 million before manufacturer rebates, about $1,146 per prescription, and the most-filled product was Ozempic. These counts include diabetes prescriptions, not only weight loss. Wegovy, Zepbound and Saxenda, the brands approved for chronic weight management, made up 5,475 of those prescriptions (3.1%). Wegovy and Zepbound also carry other approved uses, so this is an upper bound on weight-loss use, not a count of it.

From 2021 to 2025, Connecticut Medicaid GLP-1 prescriptions went from 53,333 to 174,430, 3.3 times the 2021 count. From 2024 to 2025 the count fell by 39,234.

2021

53,333

2022

86,952

2023

154,757

2024

213,664

2025

174,430

ProductCT Medicaid prescriptions, 2025Share
Ozempic101,85358.4%
Mounjaro50,32728.9%
Trulicity13,0877.5%
Zepbound3,3501.9%
Rybelsus3,0831.8%
Wegovy2,1251.2%
Victoza3560.2%
Liraglutide (generic)2490.1%

Source: CMS State Drug Utilization Data, 2025 (updated July 13, 2026), fee-for-service and managed care, all four quarters, compiled in our network's PriceTracker GLP-1 state table (read October 4, 2026); 2021 to 2024 summed by us from CMS's own yearly datasets with the same method, read November 9, 2026. CMS hides rows under 11 prescriptions, so small counts are slightly low. CMS publishes no per-enrollee rate here, so a total reflects the size of the program as much as use.

Connecticut Employee Plan and Insurer GLP-1 Rules

We have not read the Connecticutstate employee health plan's own documents, so we do not state whether it covers GLP-1s for weight loss. State employees can ask their benefits office or check the plan's drug list.

We have no Connecticutinsurer policy on record yet. Most commercial plans decide GLP-1 coverage plan by plan, so the employer's choice matters as much as the insurer.

Comparing self-pay programs in Connecticut?

2-minute quiz: filter by budget and medication preference.

Take the quiz →

Telehealth Programs to Check for Connecticut

We list 49 programs here. 21 are recorded as available in all 50 states. 7 more publish their own state list, summarized below for Connecticut. The rest record a state count without naming the states, so confirm Connecticut with the program at intake before you pay.

What Programs' Own Pages Say About Connecticut

8 of the 8 programs whose own pages name the states they serve include Connecticut: Willow, SnagRx, Strut Health, MangoRx, Wellorithm, MEDGm, TelosRx, Trimi. Pages read November 9, 2026. This is what each seller states about availability, not a licensing check.

Trimi's state table lists Connecticut as served through the Arora Health network. Visit format there: Online intake reviewed by a licensed provider; no in-person visit required. The telehealth law it cites for Connecticut is Conn. Gen. Stat. 19a-906(b)(1). That citation is Trimi's, not our legal reading. Trimi state table, read November 9, 2026.

Programs on Our List, in Published Order

Compounded GLP-1 care with one-month and prepaid plans

Personalized GLP-1 consultations with tailored prescriptions and ongoing physician support

Affordable compounded semaglutide from $119/mo with free shipping and health coaching

From $119/mo semaglutide, from $185/mo tirzepatide, 12-month planCompounded Semaglutide, Compounded TirzepatideAll 50 States

Personalized GLP-1 weight loss with licensed providers and nationwide coverage

45 more programs on our list: 19 recorded as available in all 50 states, 7 with a state list shown in the table above, and 19 with a state count but no published list we have read. Compare all of them side by side.

Estimated GLP-1 Costs in Connecticut

Best Value

Telehealth (Compounded)

$79 to $399/mo

Recorded monthly-plan prices for compounded semaglutide and tirzepatide. Availability varies by program, so confirm your state at intake.

Wegovy

Brand prices with and without insurance.

Zepbound

List, LillyDirect and savings card prices.

No insurance

Self-pay GLP-1 options without coverage.

The compounded range is our recorded monthly-plan prices, the same in every state. Brand and insurance costs depend on the plan, so we link the pages that carry their sources. Compounded medications are not FDA-approved.

Medicare Part D GLP-1 Claims in Connecticut, 2024

Connecticut prescribers wrote 265,056 Medicare Part D GLP-1 claims in 2024, number 27 of 51, with $355.7 million in gross drug cost before rebates. Ozempic led with 138,165 claims for 25,910 enrollees. Wegovy had 3,061 claims. Part D did not pay for weight loss alone in 2024, so these fills are for diabetes and other approved uses.

ProductCT Part D claimsEnrollees
Ozempic138,16525,910
Mounjaro61,35111,063
Trulicity44,5878,876
Rybelsus12,8423,343
Wegovy3,061778
Victoza2,378Not given
Bydureon Bcise1,929430
Liraglutide613244
Byetta13029

Source: CMS Medicare Part D Prescribers by Geography and Drug, 2024 (updated May 21, 2026), state rows, read November 9, 2026. The state is the prescriber's. Claims include refills, and enrollees are not added across products because one person can fill two.

Now Live — Launched July 1, 2026

Medicare GLP-1 Bridge Program in Connecticut

The Bridge is national, so the rules are the same in Connecticut as everywhere: eligible Part D enrollees pay $50/month for Foundayo, Wegovy or Zepbound KwikPen, subject to BMI rules and exclusions. Medicare fact sheet.

Patient Cost

$50/mo

Launch Date

July 1, 2026

Runs Through

Dec 31, 2027

Read the Full Medicare Guide

How Connecticut Compares to Other Northeast States

Medicaid coverage of GLP-1s for obesity is optional for states, so the answer differs by state. Here is how Connecticut and its neighbors in the Northeast are recorded:

StateMedicaid and GLP-1s for obesityMedicaid GLP-1 Rx, 2025
Connecticut (this page)Not covered174,430
MassachusettsNot covered399,014
New JerseyNot covered165,515
New YorkNot covered815,882
PennsylvaniaNot covered843,743

Our recorded telehealth prices are not state-specific: $79 to $399/month on monthly plans. Medicaid and marketplace coverage is what varies.

KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026. Managed care plans may differ. Later counts may be lower: The RX Index, an independent tracker, listed 11 in a July 10, 2026 snapshot and says that is not a current national count. Sources read November 6, 2026. Policies change, so confirm with your state Medicaid agency or plan.

If Your Insurance Denies GLP-1 Coverage in Connecticut

Commercial plans offer an internal appeal, then external review; Connecticut Medicaid enrollees can ask for a fair hearing. The denial letter names the deadlines.

How to Check Your Specific Plan in Connecticut

  • Connecticut Medicaid: Medicaid: not covered as of January 2026 (KFF). Ask your Medicaid plan for its drug list and prior authorization rules, or find the state agency on Medicaid.gov's state contacts.
  • State employees: we have not read the plan's documents; ask the benefits office.
  • Any other plan: call the number on your card and ask whether Wegovy or Zepbound is covered for weight loss, which tier it sits on, and what prior authorization needs. Get the answer in writing.

Find the Right GLP-1 Provider in Connecticut

Answer a few questions and we'll match you with the best GLP-1 program for your budget, insurance, and goals in Connecticut.

Frequently Asked Questions — Connecticut

Does Connecticut Medicaid cover GLP-1 medications for weight loss?
KFF's map lists Connecticut as not covering GLP-1s for obesity under fee-for-service as of January 2026. KFF notes the state reported covering one or more weight-loss drugs, but no GLP-1s. Rules and later changes are not on that map, so confirm with the state Medicaid agency or your plan. You can also look at telehealth programs (recorded monthly-plan prices from $79/month; confirm Connecticut at intake), commercial insurance, or the Medicare GLP-1 Bridge.
How many GLP-1 prescriptions did Connecticut Medicaid pay for in 2025?
Connecticut Medicaid paid for 174,430 GLP-1 prescriptions in 2025, 1.5% of the 11.26 million paid nationally and number 16 of 51 (50 states and DC). It reimbursed pharmacies $199.9 million before manufacturer rebates, about $1,146 per prescription, and the most-filled product was Ozempic. These counts include diabetes prescriptions, not only weight loss. Wegovy, Zepbound and Saxenda, the brands approved for chronic weight management, made up 5,475 of those prescriptions (3.1%). Wegovy and Zepbound also carry other approved uses, so this is an upper bound on weight-loss use, not a count of it. From 2021 to 2025, Connecticut Medicaid GLP-1 prescriptions went from 53,333 to 174,430, 3.3 times the 2021 count. From 2024 to 2025 the count fell by 39,234. Source: CMS State Drug Utilization Data, 2025 (updated July 13, 2026).
How many Medicare Part D GLP-1 claims were there in Connecticut in 2024?
Connecticut prescribers wrote 265,056 Medicare Part D GLP-1 claims in 2024, number 27 of 51, with $355.7 million in gross drug cost before rebates. Ozempic led with 138,165 claims for 25,910 enrollees. Wegovy had 3,061 claims. Part D did not pay for weight loss alone in 2024, so these fills are for diabetes and other approved uses. Source: CMS Medicare Part D Prescribers by Geography and Drug, 2024 (updated May 21, 2026).
What is the cheapest way to get GLP-1 medication in Connecticut?
The lowest monthly-plan price we have recorded among programs on this page is $79/month (Embody, compounded semaglutide, monthly plan). Embody lists 48 states and our records do not name them, so confirm Connecticut at intake. Medicare Part D enrollees who qualify can get Foundayo, Wegovy or Zepbound KwikPen for $50/month through the Bridge.
Which online GLP-1 programs serve Connecticut?
8 of the 8 programs whose own pages name the states they serve include Connecticut: Willow, SnagRx, Strut Health, MangoRx, Wellorithm, MEDGm, TelosRx, Trimi. Pages read November 9, 2026. For the other programs on this page, confirm Connecticut at intake before you pay.
Does Medicare cover GLP-1s in Connecticut?
Yes for eligible Part D enrollees in Connecticut: $50/month through the Medicare GLP-1 Bridge, July 1, 2026 to December 31, 2027, under the BMI rules in the Medicare section above.

Ready to start?

Compare the recorded costs, sources and evidence gaps for 52 listed providers. Confirm current terms with the provider before enrolling.

Embody (paid link)

from $49/mo, 12-month plan

Visit Embody